the burden imposed on caregivers and society, especially in aging populations. Yet, there is a relative paucity of high-quality studies evaluating the link between diabetes and stroke.
In this issue of the European Heart Journal, Echouffo-Tcheugui et al. report on long-term outcomes after stroke in diabetic patients from the Get With The Guidelines-Stroke registry, the largest U.S. database on stroke. They found that after an ischaemic stroke, patients with diabetes, as compared to those without, experienced higher risk of death and hospitalization for cardiovascular or non-cardiovascular events, as well as higher rates of readmission for stroke recurrence. 2 We argue that three key questions emerge from these findings ( Figure 1) .
Firstly, is this association robust? Not all previous studies investigating the long-term outcome after stroke have identified diabetes as a significant determinant. Thus, it is important to highlight why the paper by Echouffo-Tcheugui et al. deserves credit. First, the sample size is very large and representative, including >409 000 patients. Second, Get With The Guidelines-Stroke is a prospective registry, wherein participating hospitals use an online case report form to send data of consecutive ischaemic stroke patients to the central database. This design warrants substantially higher data quality than retrospective studies using only administrative databases or electronic charts with data acquired during routine clinical practice and not for research purposes. Third, only patients with the ischaemic stroke subtype were included, thereby limiting heterogeneity arising from the different outcome determinants of haemorrhagic stroke. Finally, confounding variables intrinsic to the different clinical characteristics of diabetic vs. non-diabetic patients have been robustly adjusted with both multivariate analysis and propensity score matching.
Yet, the study has limitations that we should be aware of before drawing any definite conclusions. Only patients aged > _65 years were included because the registry is linked to the Centres for Medicare & Medicaid Services claims. Although most ischaemic stroke events occur within this age category, the outcome of stroke in younger people may be even more important because of its impact on working capacity and years spent with disability. The methodological approach might also be subjected to bias. The databases were linked by indirect case-related information instead of a univocal identifier, leaving room for mislinkage. Finally, despite careful statistical analysis, residual confounders may remain, implying that part of the poorer outcomes of diabetic patients may be attributable to comorbid conditions and/or peculiar patient characteristics, and not to diabetes per se.
Secondly, what drives such a poor outcome? Provided that a true link exists between diabetes and poor long-term outcome after ischaemic stroke, questions remain on what causes this association. Hyperglycaemia is probably a mediator of neurological worsening in acute stroke because of its negative effects on the vulnerable brain circulation during ischaemia. Evidence for an acute role of hyperglycaemia is supported by data on the negative impact of stress hyperglycaemia on mortality and functional recovery in non-diabetic stroke survivors. 3 The study by Echouffo-Tcheugui et al. short-term outcomes, but can have little effect on the 3-year rate of hard endpoints. We should keep in mind that diabetes leads to multiorgan pathologies that cumulatively reduce life expectancy. In addition to the risk of CVD, diabetes increases mortality from renal, gastrointestinal, neurologic, pulmonary, and infectious diseases. 4 It is therefore not surprising that people with diabetes, after an insult that makes them even more fragile like ischaemic stroke, experience a higher rate of death from cardiovascular and non-cardiovascular causes. From a pathophysiological perspective, it has been proposed that hyperglycaemia activating myelopoiesis facilitates inflammation to the vessel wall and, hence, atherosclerosis. 5 This haematopoietic activation is part of a vicious circle whereby acute vascular events like stroke, perpetuating atherosclerosis, enhance the risk of future events. 6 Moreover, such an inflammatory haematopoiesis is mechanistically linked to pauperization of bone marrow-derived stem cells, a major driver of diabetes-associated cardiovascular risk. 7 In addition, a large body of experimental evidence has highlighted the role of p66
Shc as a key driver of mitochondrial oxidative stress and vascular damage linking diabetes to poor cardiovascular outcomes. p66
Shc -deficient diabetic mice are protected against hyperglycaemia-induced endothelial dysfunction and redox changes.
Deletion of p66
Shc also protects from systemic and cerebral agedependent endothelial dysfunction, by virtue of decreased reactive oxygen species (ROS) production and preserved nitric oxide availability. 8 p66 Shc has also been associated with the pathogenesis of stroke: cerebral ROS production and stroke size following ischaemia-reperfusion brain injury is reduced in p66 Shc-/-mice, 9 or by in vivo silencing of p66 Shc . 10 The recent observation that p66 Shc expression increases in blood cells of patients with stroke 10 and type 2 diabetes 11 supports the clinical relevance of these experimental findings.
Altogether, these biological pathways may provide a better understanding of the driving forces underlying the burden of CVD complications in this setting.
Thirdly, how can we make an impact on this deadly pair? There is strong evidence that stroke incidence and mortality can be reduced by effective blood pressure control in diabetic, as in non-diabetic, individuals. Although stroke outcome is worse in patients with poorly controlled diabetes, there is no clear evidence that strict glucose control improves cardiovascular outcomes. Nonetheless, recent cardiovascular outcome trials (CVOTs) provide new information about glucose lowering treatment and stroke incidence in diabetic patients at high cardiovascular risk, or with established CVD.
In the EMPA-REG Outcome trial and in the CANagliflozin cardioVascular Assessment STudy (CANVAS) trial programme, diabetic patients randomized to receive a sodium-glucose cotransporter-2 (SGLT2) inhibitor (empagliflozin or canagliflozin, respectively) experienced a lower rate of major adverse cardiovascular events (MACE) than those randomized to placebo. 12, 13 However, no protection from stroke was observed, but rather a trend toward increased rates of non-fatal stroke was found in the group treated with empagliflozin. 13 In the Liraglutide Effect and Action in Diabetes:
Evaluation of cardiovascular outcome Results (LEADER) trial, patients randomized to the long-acting GLP-1 receptor agonist (GLP-1RA) liraglutide vs. placebo also displayed a reduced risk of MACE, with stroke rates following the same favourable trend as the primary outcome. 14 Interestingly enough, the smaller SUSTAIN-6 trial, with the even longer acting and more potent GLP-1RA semaglutide, showed a significant reduction in MACE mainly driven by a reduction in non-fatal stroke. 14 Finally, the Insulin Resistance Intervention after Stroke (IRIS) trial was specifically designed to evaluate whether pioglitazone reduced the risk of ischaemic stroke or transient ischaemic attack (TIA) in non-diabetic patients with insulin resistance, and a recent ischaemic stroke or TIA. 15 The results indicated a 24% reduction in stroke/TIA recurrence in patients randomized to pioglitazone vs. placebo. 15 Thus, although evidence is emerging for stroke prevention using diabetes drugs, new glucose-lowering medications appear to differ in their protective effects against stroke. Up to 30% of ischaemic stroke events occur in patients with diabetes. The evidence that diabetes worsens the long-term outcome after such an event, along with the notion that many patients presenting with ischaemic stroke have previously unrecognized diabetes, is a call for action.
Diabetes is a complex disorder with multifaceted and competing CVD manifestations. Studies on CVD in diabetes have been mainly focused on ischaemic heart disease, and scotomizing endpoints like peripheral arterial disease and stroke. Particularly worrisome is the risk of hospitalization for heart failure (HHF) in ischaemic stroke survivors with diabetes. Nowadays, new preventive, diagnostic, and therapeutic opportunities are emerging to improve the care of diabetic patients after ischaemic stroke. However, paradoxically, the use of SGLT2 inhibitors to prevent HHF in type 2 diabetes is not lowering stroke risk but may even increase it, 13 whereas glucose-lowering medications with potential benefits on stroke risk exert no protection against HHF (GLP-1RA) 14 or may increase HHF risk (pioglitazone). 15 These striking examples of competing cardiovascular outcomes in patients with diabetes suggest that randomized controlled trials should look beyond simplistic composite endpoints and, especially, explore combination therapies that may be particularly effective. Comprehensive management of CVD in diabetes remains a moving target and, hence, a major therapeutic challenge.
